KAIROS PHARMA, LTD. — Operating Income by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0b807a2e-7086-40f7-8c5b-575b7d3567df/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-5.6M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-014159 |
| FY 2024 | $-2.3M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-004920 |
| FY 2023 | $-1.7M | 2023-01-01 – 2023-12-31 | evidence 0001641172-25-004920 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).